Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Serial Passaging Drives Inflammatory-Metabolic Reprogramming and Replicative Senescence in Human Umbilical Cord Mesenchymal Stem Cells.

Created on 11 Nov 2026

Authors

XiaoXin Wang, BenJiao Gong, YuXiao Zhang, JiaLu Wei, JiaLe Dong, XueXia Liu, FuJun Liu

Published in

Stem cells and development. Pages 15473287261504662. Nov 11, 2026. Epub Nov 11, 2026.

Abstract

Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) are widely used in regenerative medicine, but in vitro expansion alters their molecular and functional properties. Understanding replicative senescence trajectories is critical for optimizing cell manufacturing. We performed longitudinal RNA sequencing across passages P3, P6, P9, P12, and P15, using P6 as a clinical reference. Transcriptomic dynamics were bioinformatically analyzed and validated by targeted quantitative real-time PCR. Functional assays assessed senescence-associated β-galactosidase (SA-β-gal) activity, mitochondrial membrane potential, iron accumulation, and glucose uptake. Transcriptomic profiling revealed progressive, passage-dependent divergence with an inflection point after P9. Late-passage cells (P12, P15) exhibited coordinated upregulation of proinflammatory pathways (TNFα, IL-17, and MAPK) and senescence programs, alongside downregulation of oxidative phosphorylation and autophagy. Functional validations confirmed that P12 cells acquired a senescent phenotype: enhanced SA-β-gal, mitochondrial depolarization, iron overload, and a glycolytic shift. Molecular analyses corroborated increased expression of senescence-associated secretory phenotype factors (IL6, CCL2) and glucose transporters (SLC2A1), with suppression of mitochondrial genes (MT-CO2, MT-ND4). P6 cells maintained stable profiles and robust integrity. Serial passaging drives hUC-MSCs toward senescence through bidirectional reprogramming of inflammation and metabolism. Our findings identify P6-P9 as a safe manufacturing window and propose metabolic and iron-related markers for quality control of clinical-grade MSCs, ensuring therapeutic potency.

PMID:
43012623
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement